MBX · MBX Biosciences, Inc.

Track MBX — free

$56.55 -2.07 (-3.53%) At close · Oct 1

Russell 2000 member Rebalance outlook locked

Market Cap

$2.58B

48.16M

Volume · Oct 1 434.15K Avg daily vol (3M) 566.15K

Up next

Next earnings call

Oct 20, 2026 Est · unconfirmed · in 3 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2025 earnings call transcript

call held Sep 22, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$104.32M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-3.3%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$418.58M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+42.6%

Year over year · more shares

Price change (1Y)

+235.0%

Trailing year

Short interest

8.6%

Latest settlement · 11.4 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Sell Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 16.4 · calm Equity put/call 0.57

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg +30%

above

Price vs 50-day avg −11%

below

RSI (14) 41

neutral

MACD trend Negative

52-week position 75%

mid-range

Momentum

relative strength

Strong

1-month return −7%

trailing

6-month return +82%

trailing

YTD return +79%

this year

Relative strength +70%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $63 › 200d $43 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +39 funds added

Insider flow Distributing

Net -$24.3K over 90 days · 100% sells

Short interest Falling

8.58% of float · ▼ -0.6% MoM · 11.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

175 holders — near 2-yr high, broad support

Squeeze score 61

elevated · 0–100

Fundamentals

Fair

EPS growth +59%

Y/Y

Free cash flow $-81.9M

Quant / Vol

risk profile

Very High

Volatility 80%

annualized · 1-yr

Max drawdown −38%

past year

ATR 6.0%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

2 · 3 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+30% Bullish

Price vs 50-day avg

−11% Bearish

RSI (14)

41 Neutral

MACD trend

Negative Bearish

52-week position

75% Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $63 › 200d $43 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +39 funds added

Insider flow Distributing

Net -$24.3K over 90 days · 100% sells

Short interest Falling

8.58% of float · ▼ -0.6% MoM · 11.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

175 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $13 Now $57 · 75% Range high $71

vs 200-day avg +30% vs 50-day avg -11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MBX MBX Biosciences, Inc. this stock	$2.58B	+79.3%	—	—	8.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.8%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+540.7%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

175

% held: 116.4%
Net QoQ: +3.4M sh
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

206

View

Short & Settlement

Short Interest Falling

Shares short

4.1M

Days to cover: 11.4d
Change: -25.7K sh

View

Short Volume

Short vol %

76%

As of: Oct 1, 2026

Short Total

View

Fails to Deliver

FTD shares

100

Value: $6.1K
As of: Sep 4, 2026

View

Off-Exchange

Off-exchange %

48.2%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$24.3K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-87.0M

EPS diluted: $-2.38

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 16, 2026
This year: 21

View

Proposed Sales

Value

$255.7K

Shares: 3.7K
Filed: Aug 17, 2026

View

Exempt Offerings

Offering

$115.2M

Filed: Nov 18, 2022

View

Earnings & Events

Webcasts

Last webcast

Sep 16, 2026

View

Performance

	5D	20D	120D	MTD	YTD
MBX	+2.1%	-7.1%	+82.4%	-3.5%	+79.3%
SPY	-0.4%	-0.2%	+12.4%	+0.2%	+12.0%
vs SPY	+2.5%	-7.0%	+70.0%	-3.7%	+67.3%

Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 3 filings 3 filers Visit website Investor relations

MBX · MBX Biosciences, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance